Biomea Fusion is trading at $0.67, up 7.58% after the October 29 regular-session close, with no clear company-specific catalyst identified.

  • The company’s latest listed release, dated October 13, reports Phase 1 BMF-650 results; it is not a new October 29 announcement.
  • Broader market signals were mixed: the S&P 500 fell 0.83%, while the Nasdaq Composite rose 1.17%; neither clearly explains the stock’s gain.